Frédéric Guyon

Dr. Frédéric Guyon


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2022 in Gynecologic Oncology
Verified
Journal Article
Closed access
MAMartina Angeles
Martina Angeles
AHAlicia Hernández
Alicia Hernández
PAPEREZ-BENAVENTE ASUNCION
PEREZ-BENAVENTE ASUNCION
BCBastien Cabarrou
Bastien Cabarrou
ESEmanuela Spagnolo
Emanuela Spagnolo
AMAlejandra Martinez
Alejandra Martinez

10 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ELEric Leblanc
Eric Leblanc
FNFabrice Narducci
Fabrice Narducci
GFGwénaël Ferron
Gwénaël Ferron
AMAudrey Mailliez
Audrey Mailliez
JCJean-Yves Charvolin
Jean-Yves Charvolin
DHDelphine Hudry
Delphine Hudry
Risk-reducing salpingo-oophorectomy is the gold standard for the prophylaxis of ovarian cancer in high-risk women. Due to significant adverse effects, 20–30% of women delay or refuse early oophorectomy. This prospective pilot study (NCT01608074) aimed to assess the efficacy of radical fimbriectomy followed by a delayed oophorectomy in preventing ovarian and pelvic invasive cancer (the primary endpoint) and to evaluate the safety of both procedures. The key eligibility criteria were pre-menopausal women ≥35 years with a high risk of ovarian cancer who refused a risk-reducing salpingo-oophorectomy. All the surgical specimens were subjected to the SEE-FIM protocol. From January 2012 to October 2014, 121 patients underwent RF, with 51 in an ambulatory setting. Occult neoplasia was found in two cases, with one tubal high-grade serous ovarian carcinoma. Two patients experienced grade 1 intraoperative complications. No early or delayed grade ≥3 post-operative complications occurred. After 7.3 years of median follow-up, no cases of pelvic invasive cancer have been noted. Three of the fifty-two patients developed de novo breast cancer. One BRCA1-mutated woman delivered twins safely. Twenty-five patients underwent menopause, including fifteen who had received chemotherapy for breast cancer, and twenty-three underwent menopause before the delayed oophorectomy, while two did not undergo a delayed oophorectomy at all. Overall, 46 women underwent a delayed oophorectomy. No abnormalities were found in any delayed oophorectomy specimens. Radical fimbriectomy followed by delayed oophorectomy appears to be a safe and well-tolerated risk-reducing approach, which avoids early menopause for patients with a high risk of breast and ovarian cancer.

20 December 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CMChrysoula Margioula-Siarkou
Chrysoula Margioula-Siarkou
AAAristarchos Almperis
Aristarchos Almperis
Giuseppe GulloGiuseppe Gullo
Giuseppe Gullo
EAEmmanouela-Aliki Almperi
Emmanouela-Aliki Almperi
GMGeorgia Margioula-Siarkou
Georgia Margioula-Siarkou
SPStamatios Petousis
Stamatios Petousis
Cervical cancer (CC) continues to be a significant global public health concern, even with preventive measures in place. In women with early-stage CC, the status of lymph nodes is of paramount importance, not only for the final prognosis but also for determining the best therapeutic strategy. According to main international guidelines, pelvic full lymphadenectomy (PLND) is recommended for lymph node staging. However, in these early stages of CC, sentinel lymph node biopsy (SLNB) has emerged as a precise technique for evaluating lymph node involvement, improving its morbidity profile. We performed a literature review through PubMed articles about progress on the application of SLNB in women with early-stage CC focusing on the comparison with PET/CT and PLND in terms of oncological outcomes and diagnostic accuracy. While the superiority of SLNB is clear compared to radiologic modalities, it demonstrates no clear oncologic inferiority over PLND, given the higher detection rate of positive lymph nodes and predominance of no lymph node recurrences. However, due to a lack of prospective evidence, particularly concerning long-term oncological safety, SLNB is not the current gold standard. With careful patient selection and adherence to straightforward protocols, a low false-negative rate can be ensured. The aim of the ongoing prospective trials is to address these issues.

9 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
KHKhalil Hodroj
Khalil Hodroj
ASAleksandra Stevovic
Aleksandra Stevovic
VAValery Attignon
Valery Attignon
DFDomenico Ferraioli
Domenico Ferraioli
PMPierre Meeus
Pierre Meeus
IRIsabelle Ray-Coquard
Isabelle Ray-Coquard
Most patients with malignant ovarian germ cell tumors (MOGTCs) have a very good prognosis and chemotherapy provides curative treatment; however, patients with yolk sac tumors (OYSTs) have a significantly worse prognosis. OYSTs are rare tumors and promising results are expected with the use of specific therapeutic strategies after the failure of platinum-based first-line and salvage regimens. We initiated a project in collaboration with EORTC SPECTA, to explore the molecular characteristics of OYSTs. The pilot project used retrospective samples from ten OYST relapsed and disease-free patients. Each patient had a molecular analysis performed with FoundationOne CDx describing the following variables according to the Foundation Medicine Incorporation (FMI): alteration type (SNV, deletion), actionable gene alteration, therapies approved in EU (for patient’s tumor type and other tumor types), tumor mutational burden (TMB), and microsatellite instability (MSI) status. A total of 10 patients with OYST diagnosed between 2007 and 2017 had a molecular analysis. A molecular alteration was identified in four patients (40%). A subset of three patients (33.3% of all patients) harbored targetable oncogenic mutations in KRAS, KIT, ARID1A. Two patients at relapse harbored a targetable mutation. This retrospective study identifies clinically relevant molecular alterations for all relapsed patients with molecular analysis. Dedicated studies are needed to demonstrate the efficacy of specific therapeutic strategies after the failure of platinum-based first-line and salvage regimens and to explore the potential relationship of a molecular alteration and patient outcome.

1 January 2021 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
MAMartina Angeles
Martina Angeles
BCBastien Cabarrou
Bastien Cabarrou
Antonio Gil-MorenoAntonio Gil-Moreno
Antonio Gil-Moreno
PAPEREZ-BENAVENTE ASUNCION
PEREZ-BENAVENTE ASUNCION
ESEmanuela Spagnolo
Emanuela Spagnolo
AMAlejandra Martinez
Alejandra Martinez
Angeles MA, et al. J Gynecol Oncol. 2021 Aug;32:e78. https://doi.org/10.3802/jgo.2021.32.e78

27 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MMMathilde Mairé
Mathilde Mairé
ABAurélien Bourdon
Aurélien Bourdon
ISIsabelle Soubeyran
Isabelle Soubeyran
Carlo LUCCHESICarlo LUCCHESI
Carlo LUCCHESI
FGFrédéric Guyon
Frédéric Guyon
SCSabrina Croce
Sabrina Croce
Introduction. Lymph node metastasis is determinant in the prognosis and treatment of endometrioid endometrial cancer (EEC) but the risk–benefit balance of surgical lymph node staging remains controversial. Objective. Describe the pathways associated with lymph node metastases in EEC detected by whole RNA sequencing. Methods. RNA-sequencing was performed on a retrospective series of 30 non-metastatic EEC. N+ and N− patients were matched for tumoral size, tumoral grade and myometrial invasion. Results. Twenty-eight EECs were analyzable (16 N+ and 12 N−). Bioinformatics Unsupervised analysis revealed three patterns of expression, enriched in N+, mix of N+/N− and enriched in N−, respectively. The cluster with only N+ patient overexpressed extra cellular matrix, epithelial to mesenchymal and smooth muscle contraction pathways with respect to the N− profile. Differential expression analysis between N+ and N− was used to generate a 54-genes signature with an 87% accuracy. Conclusion. RNA-expression analysis provides a basis to develop a gene expression-based signature that could pre-operatively predict lymph node invasion.